GlassScriptPhysician profile
Shiraz Farooq
NPI 1205970431
$2,231.86
in general payments reported to CMS, 2019-2025
15 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $278 · 2021: $195 · 2022: $675 · 2023: $172 · 2024: $19.66 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thd America, INC. | $555.36 | 2022-2025 | |
| Axonics, INC. | $461.24 | 2020-2022 | |
| Palette Life Sciences, INC. | $226.02 | 2021-2022 | |
| Medtronic, INC. | $165.99 | 2022 | |
| Ethicon US, LLC | $141.49 | 2022 | |
| Genentech USA, INC. | $141.17 | 2019 | |
| Bioness INC | $125.99 | 2019 | |
| Hologic Sales and Service, LLC | $125.00 | 2025 | Coolseal Generator |
| Medical Device Business Services, INC. | $83.15 | 2022 | |
| Amgen INC. | $74.62 | 2019 | |
| Redhill Biopharma INC. | $71.89 | 2022-2024 | Talicia, Aemcolo |
| Trevena, INC. | $33.54 | 2022 | |
| Boston Scientific Corporation | $26.40 | 2025 | Axonics |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiraz Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.